The goal of the Career Development Program is to prepare physicians and scienfists for independent careers in translafional research in sarcoma. It is our hope that the women and men funded through this process will spend their professional lifefimes conducfing translational research specifically in this set of diseases and that they will become leaders in their fields of interest. Memorial Sloan-Kettering Cancer Center (MSKCC) is ideally suited for this task, with substantial physical and faculty resources and more than a century of experience training physicians and scientists of the highest quality. Our institufional environment includes a K12 for translational science training and a K30 for the training of clinical investigators. In the Career Development Program, we plan to enhance the formal training programs that already exist at MSKCC. We will encourage more physicians to focus on translafional research in sarcoma and will similariy strive to attract basic scientists to devote postdoctoral fellowship training to this quickly evolving field. We will also provide partial support for two new junior faculty investigators every 2 to 3 years who commit their careers to translational research in sarcoma. In our efforts to recruit these invesfigators, we will draw upon existing programs at MSKCC that recruit, train, and mentor postgraduate scientists and physician-scientists. We will budget at least $150,000 yearly for this program, including $50,000 from the SPORE award itself and at least $100,000 in funds pledged by MSKCC. To continually educate both trainees and SPORE staff, we will utilize regulariy scheduled conferences, data presentations by members of the SPORE research projects and cores, and presentafions by invited speakers. The Career Development Program will be directed by a Career Development Committee, chaired by Dr. David Spriggs and Dr. Robert Maki.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA140146-02
Application #
8314130
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2011-07-01
Budget End
2012-06-30
Support Year
2
Fiscal Year
2011
Total Cost
$44,215
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Klein, Mary E; Dickson, Mark A; Antonescu, Cristina et al. (2018) PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence. Oncogene 37:5066-5078
Banito, Ana; Li, Xiang; Laporte, Aimée N et al. (2018) The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma. Cancer Cell 34:346-348
Klein, Mary E; Kovatcheva, Marta; Davis, Lara E et al. (2018) CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought. Cancer Cell 34:9-20
Kao, Yu-Chien; Owosho, Adepitan A; Sung, Yun-Shao et al. (2018) BCOR-CCNB3 Fusion Positive Sarcomas: A Clinicopathologic and Molecular Analysis of 36 Cases With Comparison to Morphologic Spectrum and Clinical Behavior of Other Round Cell Sarcomas. Am J Surg Pathol 42:604-615
Owosho, Adepitan A; Zhang, Lei; Rosenblum, Marc K et al. (2018) High sensitivity of FISH analysis in detecting homozygous SMARCB1 deletions in poorly differentiated chordoma: a clinicopathologic and molecular study of nine cases. Genes Chromosomes Cancer 57:89-95
Suurmeijer, Albert J H; Dickson, Brendan C; Swanson, David et al. (2018) A novel group of spindle cell tumors defined by S100 and CD34 co-expression shows recurrent fusions involving RAF1, BRAF, and NTRK1/2 genes. Genes Chromosomes Cancer 57:611-621
Bennett, Jennifer A; Braga, Ana C; Pinto, Andre et al. (2018) Uterine PEComas: A Morphologic, Immunohistochemical, and Molecular Analysis of 32 Tumors. Am J Surg Pathol 42:1370-1383
Kao, Yu-Chien; Fletcher, Christopher D M; Alaggio, Rita et al. (2018) Recurrent BRAF Gene Fusions in a Subset of Pediatric Spindle Cell Sarcomas: Expanding the Genetic Spectrum of Tumors With Overlapping Features With Infantile Fibrosarcoma. Am J Surg Pathol 42:28-38
Zhang, Jennifer Q; Zeng, Shan; Vitiello, Gerardo A et al. (2018) Macrophages and CD8+ T Cells Mediate the Antitumor Efficacy of Combined CD40 Ligation and Imatinib Therapy in Gastrointestinal Stromal Tumors. Cancer Immunol Res 6:434-447
Fittall, Matthew W; Mifsud, William; Pillay, Nischalan et al. (2018) Recurrent rearrangements of FOS and FOSB define osteoblastoma. Nat Commun 9:2150

Showing the most recent 10 out of 169 publications